Evidence map›Paper›PMID 39581892›Full record

Observational studyBreast cancer research and treatment2025

Real-world quality-of-life of patients with HR+/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS.

Gabrielle B Rocque, Joanne L Blum, Yan Ji, Timothy Pluard, John Migas, Shailendra Lakhanpal, Erin Jepsen, Eric Gauthier, Yao Wang, Monica Z Montelongo and 3 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03280303 (POLARIS), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03280303 completednot on this map

Polaris: palbociclib in hormone receptor positive advanced breast cancer: a prospective multicenter non-interventional study

TypeobservationalSponsorPfizerRan2017 to 2022Enrolled1,285ConditionsAdvanced Breast Cancer, Metastatic Breast CancerArmsnon-interventional
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Observational
  3. Observational
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gabrielle B RocqueUniversity of Alabama at Birmingham, Birmingham, AL, USA. grocque@uabmc.edu.
Joanne L BlumBaylor-Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX, USA.
Yan JiHealth Partners Institute, St. Paul, MN, USA.
Timothy PluardSaint Luke's Cancer Institute, Kansas City, MO, USA.
John MigasMid-Illinois Hematology &, Oncology Associates Ltd, Normal, IL, USA.
Shailendra LakhanpalSaint Vincent's Birmingham, Birmingham, AL, USA.
Erin JepsenNovant Health, Winston-Salem, NC, USA.
Eric GauthierPfizer Inc, San Francisco, CA, USA.
Yao WangPfizer Inc, San Diego, CA, USA.
Monica Z MontelongoICON Plc, Blue Bell, Harrisburg, PA, USA.
Joseph C CappelleriPfizer Inc, Groton, CT, USA.
Meghan S KaruturiThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Debu TripathyThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate patient-reported health-related quality-of-life (QoL) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced/metastatic breast cancer (ABC) treated with palbociclib in the longitudinal real-world study, POLARIS.

methodsData were prospectively collected from adult patients with HR+/HER2- ABC treated with palbociclib plus endocrine therapy (ET) in routine clinical practice. QoL was assessed with the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (EORTC QLQ-C30) and reported at baseline and months 6, 12, and 18. Data were expressed as absolute scores at a given time and change from baseline for global QoL and functional/symptom scales. Global Heath Status (GHS)/QoL scores were also determined across 6 patient subgroup categories (e.g., age, visceral disease status). Additionally, the proportions of patients with scores below (functional scales) or above (symptom scales) EORTC-validated thresholds reflecting clinical importance of a health problem were determined.

resultsAmong patients treated with palbociclib plus ET (N = 1250) who completed questionnaires at any of the study timepoints, mean GHS/QoL scores at months 6 (69.3), 12 (70.1), and 18 (69.9) were higher than baseline (64.0). Similar trends were observed for functional and symptom scales. Mean GHS/QoL scores over time were consistent across the evaluated subgroups. Decreases in the proportions of patients with clinically important functional impairment/symptoms were observed for most functional/symptom scales from baseline through month 18.

conclusionFindings from this real-world study indicate patients with HR+/HER2- ABC treated with palbociclib plus ET maintain their QoL for at least 18 months. CLINICAL

trial registrationNCT03280303; registered 12 September 2017.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsQuality of LifeAdultAgedAged, 80 and overErb-b2 Receptor Tyrosine KinasesFemaleHumansLongitudinal StudiesMiddle AgedPiperazinesProspective StudiesPyridinesReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, humanErb-b2 Receptor Tyrosine KinasespalbociclibPiperazinesPyridinesReceptors, EstrogenReceptors, ProgesteroneHR+/HER2− advanced breast cancerPalbociclibPatient-reported outcomesPOLARISQuality of lifeReal-world evidence

Identifiers

PMID39581892
PMCPMC11785676

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.